Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;143(5):1298-1306.
doi: 10.1097/PRS.0000000000005501.

The Dutch Breast Implant Registry: Registration of Breast Implant-Associated Anaplastic Large Cell Lymphoma-A Proof of Concept

Babette E Becherer  1 , Mintsje de Boer  1 , Pauline E R Spronk  1 , Annette H Bruggink  1 , Jan Paul de Boer  1 , Flora E van Leeuwen  1 , Marc A M Mureau  1 , René R J W van der Hulst  1 , Daphne de Jong  1 , Hinne A Rakhorst  1
Affiliations

The Dutch Breast Implant Registry: Registration of Breast Implant-Associated Anaplastic Large Cell Lymphoma-A Proof of Concept

Babette E Becherer et al. Plast Reconstr Surg. 2019 May.

Abstract

Background: The Dutch Breast Implant Registry (DBIR) was established in April of 2015 and currently contains information on 38,000 implants in 18,000 women. As a clinical registry, it evaluates the quality of breast implant surgery, including adverse events such as breast implant-associated (BIA) anaplastic large cell lymphoma (ALCL). To examine the efficacy of the DBIR, the capture rate of BIA-ALCL was compared to the registration of BIA-ALCL in the Dutch Nationwide Network and Registry of Histo- and Cytopathology (PALGA) as a gold standard, in combination with matching these databases to obtain complementary information.

Methods: All BIA-ALCL patients diagnosed and registered in The Netherlands in 2016 and 2017 were identified separately in the PALGA and DBIR databases. In addition, both databases were matched using indirect key identifiers. Pathologic information from the PALGA and clinical and device characteristics from the DBIR were obtained for all patients.

Results: Matching of both databases gave a capture rate of BIA-ALCL in the DBIR of 100 percent (n = 6) in 2016 and 70 percent (n = 7) in 2017. In total, 17 patients were identified in the PALGA, of which 14 patients were also identified in the DBIR; three patients were not registered; and 10 patients were registered false-positive. Of all confirmed patients, symptoms, staging results, treatment, and implant information were registered.

Conclusions: Currently, the DBIR contains 2 full registration years and captures most of the BIA-ALCL patients despite overestimation. Therefore, pathology confirmation remains essential. By matching these databases, complementary clinical and implant information could be retrieved, establishing the DBIR as an essential postmarketing surveillance system for health risk assessments.

PubMed Disclaimer

Comment in

References

    1. Spear S. The breast implant story. Ann Plast Surg. 2006;56:573–583.
    1. European Commission. Guidelines for conformity assessment of breast implants according to directive 93/42/EEC relating to medical devices. Available at: https://ec.europa.eu/docsroom/documents/10290/attachments/1/translations.... Accessed April 11, 2018.
    1. U.S. Food and Drug Administration. FDA breast implant consumer handbook: 2004. Timeline of breast implant activities. Available at: https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/Implants.... Accessed January 26, 2018.
    1. de Boer M, van Leeuwen FE, Hauptmann M, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol. 2018;4:335–341.
    1. Agence Francaise de sécurité sanitaire des produits de santé. Situation update on checking procedures performed by the health authorities on the Poly Implant Prothèse company. Available at: https://www.ansm.sante.fr/var/ansm_site/storage/original/application/e04.... Accessed January 26, 2018.

MeSH terms